Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

Journal of Clinical Investigation

Volumn 117, Issue 9, 2007, Pages 2638-2648

  Graff, Jeremy R ^a   Konicek, Bruce W ^a   Vincent, Thomas M ^b   Lynch, Rebecca L ^a   Monteith, David ^a   Weir, Spring N ^a   Schwier, Phil ^a   Capen, Andrew ^a   Goode, Robin L ^a   Dowless, Michele S ^a   Chen, Yuefeng ^a   Zhang, Hong ^b   Sissons, Sean ^a   Cox, Karen ^a   McNulty, Ann M ^a   Parsons, Stephen H ^a   Wang, Tao ^a   Sams, Lillian ^a   Geeganage, Sandaruwan ^a   Douglass, Larry E ^c   Neubauer, Blake Lee ^a   Dean, Nicholas M ^b   Blanchard, Kerry ^a   Shou, Jianyong ^a   Stancato, Louis F ^a   Carter, Julia H ^c   Marcusson, Eric G ^b   more..

^a ELI LILLY AND COMPANY   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c Wood Hudson Cancer Research Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; INITIATION FACTOR 4E; NUCLEASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CULTURE; CELL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; GENE REPRESSION; GENETIC TRANSFECTION; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BASE SEQUENCE; CELLS, CULTURED; ENDOTHELIAL CELLS; EUKARYOTIC INITIATION FACTOR-4E; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASMS; PROTEIN BIOSYNTHESIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34848901974     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI32044     Document Type: Article

References (45)

1. De Benedetti, A., and Graff, J.R. 2004. eIF4E expression and its role in malignancies and metastases. Oncogene. 23:3189-3199.
2. Mamane, Y., et al. 2004. eIF4E - from translation to transformation. Oncogene. 23:3172-3179.
3. Brunn, G.J., et al. 1997. Phosphorylation of the translational repressor PHAS-1 by the mammalian target of rapamycin. Science. 277:99-101.
4. Gingras, A.C., Kennedy, S.G., O'Leary, M.A., Sonenberg, N., and Hay, N. 1998. 4E-BP1, a repressor of the mRNA translation, is phosphorylated and inactivated by the Akt (PKB) signaling pathway. Genes Dev. 12:502-513.
5. Bjornsti, M.A., and Houghton, P.J. 2004. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer. 4:335-348.
6. Avdulov, S., et al. 2004. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell. 5:553-563.
7. Culjkovic, B., Topisirovic, I., Skrabanek, L., Ruiz-Gutierrez, M., and Borden, K.L. 2006. eIF4E is a central node of an RNA regulon that governs cellular proliferation. J. Cell Biol. 175:415-426.
8. Rosenwald, E.B., et al. 1995. Eukaryotic translation initiation factor 4E regulates expression of cyclin D at transcriptional and posttranscriptional levels. J. Biol. Chem. 270:21176-21180.
9. Rosenwald, I.B., Karatzas, A., Sonenberg, N., and Schmidt, E.V. 1993. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor eIF4E. Mol. Cell. Biol. 13:7358-7363.
10. Rousseau, D., Kaspar, R., Rosenwald, I., Gehrke, L., and Sonenberg, N. 1996. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc. Natl. Acad. Sci. U. S. A. 93:1065-1070.
11. Rosenwald, E.B., et al. 1995. Eukaryotic translation initiation factor 4E regulates expression of cyclin D at transcriptional and posttranscriptional levels. J. Biol. Chem. 270:21176-21180.
12. Rajasekhar, V.K., and Holland, E.C. 2004. Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene. 23:3248-3264.
13. De Benedetti, A., Joshi, B., Graff, J.R., and Zimmer, S.G. 1994. CHO cells transformed by the translation factor eIF4E display increased c-myc expression, but require overexpression of Max for tumorigenicity. Mol. Cell. Differ. 2:347-371.
14. Lazaris-Karatzas, A., Montine, K.S., and Sonenberg, N. 1990. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA cap. Nature. 345:544-547.
15. Zimmer, S.G., DeBenedetti, A., and Graff, J.R. 2000. Translational control of malignancy: the mRNA cap-binding protein, eIF4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res. 20:1343-1351.
16. Shantz, L.M., and Pegg, A.E. 1994. Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res. 54:2313-2316.
17. Lazaris-Karatzas, A., et al. 1992. Ras mediates translation initiation factor 4E-induced malignant transformation. Genes Dev. 6:1631-1642.
18. Ruggero, D., et al. 2004. The translation factor eIF4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 10:484-486.
19. Wendel, H.G., et al. 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 428:332-337.
20. Rinker-Schaeffer, C.W., Graff, J.R., DeBenedetti, A., Zimmer, S.G., and Rhoads, R.E. 1993. Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. Int. J. Cancer. 55:841-847.
21. Graff, J.R., Boghaert, E.R., DeBenedetti, A., Tudor, D.M., and Zimmer, S.G. 1995. Reduction of translation initiation factor 4E reduces tumor growth, invasion and metastasis of ras-transformed cloned rat embryo fibroblast. Int. J. Cancer. 60:255-263.
22. Nathan, C.A., et al. 1997. Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene. 15:1087-1095.
23. DeFatta, R.J., Nathan, C.A., and DeBenedetti, A. 2000. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope. 110:928-933.
24. Graff, J.R., et al. 1997. Translation of ODC mRNA and polyamine transport are suppressed in ras-transformed CREF cells by depleting translation initiation factor 4E. Biochem. Biophys. Res. Commun. 240:15-20.
25. Rousseau, D., Gingras, A.C., Pause, A., and Sonenberg, N. 1996. The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene. 13:2415-2420.
26. Zhang, H., et al. 2000. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat. Biotechnol. 18:862-867.
27. Geary, R.S., et al. 2001. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 296:890-897.
28. Dean, N.M., and Bennett, C.F. 2003. Antisense oligonucleotide-based therapeutics for cancer. Oncogene. 22:9087-9096.
29. Yu, R.Z., et al. 2004. Tissue disposition of 2′-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J. Pharm. Sci. 93:48-59.
30. Mamane, Y., et al. 2007. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS ONE. 2:e242.
31. Larsson, O., et al. 2006. Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure. Nucleic Acids Res. 34:4375-4386.
32. Herbert, T.P., Fahraeus, R., Prescott, A., Lane, D.P., and Proud, C.G. 2000. Rapid induction of apoptosis mediated by peptides that bind initiation factor 4E. Curr. Biol. 10:793-796.
33. Li, S., et al. 2004. Translation initiation factor 4E blocks endoplasmic reticulum-mediated apoptosis. J. Biol. Chem. 279:21312-21317.
34. Li, S., et al. 2003. Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J. Biol. Chem. 278:3015-3022.
35. Polunovsky, V.A., et al. 1996. Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol. Cell. Biol. 16:6573-6581.
36. Jiang, B.H., Zheng, J.Z., Aoki, M., and Vogt, P.K. 2000. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 97:1749-1753.
37. Jackson, C.J., and Jenkins, K.L. 1991. Type I collagen fibrils promote rapid vascular tube formation upon contact with the apical side of cultured endothelium. Exp. Cell Res. 192:319-323.
38. Bishop, E.T., et al. 1999. An in vitro model of angiogenesis: basic features. Angiogenesis. 3:335-344.
39. Chi, K.N., et al. 2005. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl. Cancer Inst. 97:1287-1296.
40. Graff, J.R., et al. 2000. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J. Biol. Chem. 275:24500-24505.
41. Majumder, P.K., and Sellers, W.R. 2005. Akt-regulated pathways in prostate cancer. Oncogene. 24:7465-7474.
42. St. Croix, B., et al. 2000. Genes expressed in human tumor endothelium. Science. 289:1197-1202.
43. Graff, J.R., et al. 2005. The protein kinase Cβ-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 65:7462-7469.
44. Carter, J.H., et al. 2004. Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin. Cancer Res. 10:3448-3456.
45. Turley, H., et al. 1998. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J. Pathol. 186:313-318.